Cara Therapeutics: Scratching At Multiple Indications In 2020 (NASDAQ:CARA) | Seeking Alpha
CR845 (Difelikefalin), A Kappa Receptors Agonist In Phase III By CARA Therapeutics: A Case Of 'Spin' In Scientific Writing? | Semantic Scholar
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus | NEJM
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
Cara Therapeutics: Scratching An Itch Left Unscratched (NASDAQ:CARA) | Seeking Alpha
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression<b>:</b> A randomized,
Difelikefalin: First Approval
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
Nephrology Journal Club on Twitter: "Difelikefalin (CR845) (KORSUVA) is a peripherally restricted, selective kappa opioid receptor agonist that exerts antipruritic effects by means of activation of kappa opioid receptors on peripheral neurons
Difelikefalin - Wikipedia
Kappa-opioid receptor-dependent changes in dopamine and anxiety-like or approach-avoidance behavior occur differentially across the nucleus accumbens shell rostro-caudal axis,Neuropharmacology - X-MOL
Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink
Peripheral kappa opioid receptor activation drives cold hypersensitivity in mice | bioRxiv
PDF) Evaluation of the abuse potential of difelikefalin, a selective kappa‐ opioid receptor agonist, in recreational polydrug users
Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink
Cara Therapeutics - Invest In Weed
Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications - ScienceDirect
1Washington University, St. Louis, MO, USA; 2Trevi Therapeutics, New Haven, CT, USA; 3University of Miami, Miami, FL, USA Introd
Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development | SpringerLink
PDF) Purification of a kappa-opioid receptor subtype from frog brain | Mária Szücs, Anna Borsodi, and Kálmán Medzihradszky - Academia.edu
Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects
Frontiers | Advances in Achieving Opioid Analgesia Without Side Effects
Articles with Cara Therapeutics, Inc. | page 5
A New Path to Pain Relief: Time for a Change with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)Friday, March 17, 201712:30 PM – 1:30 PMGrand Caribbean Ballroom 7Loews Sapphire Falls ResortOrlando, Florida Survey
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
